HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth.

Abstract
Anaplastic thyroid carcinoma (ATC) is a highly aggressive form of the disease for which new therapeutic options are desperately needed. Previously, we showed that the high-affinity peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, RS5444, inhibits cell proliferation of ATC cells via induction of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) (p21). We show here that up-regulation of RhoB is a critical step in PPARgamma-mediated activation of p21-induced cell stasis. Using multiple independently derived ATC cell lines, we found that treatment with RS5444 leads to the up-regulation of RhoB and subsequent activation of p21, and that silencing of RhoB by RNAi blocks the ability of RS5444 to induce p21 and to inhibit cell proliferation. Our results show that transcriptional regulation of RhoB by the nuclear transcription factor PPARgamma is responsible for the induction of p21 mRNA and protein. We further implicate RhoB as a key signaling effector for the growth inhibition of ATC, as treatment with a histone deacetylase inhibitor shown to increase RhoB expression in lung cancer cells caused the up-regulation of RhoB in ATC cells accompanied by increased expression of p21 and inhibition of cell proliferation; this effect occurred even in ATC cells that were unresponsive to RS5444 due to a lack of expression of PPARgamma. Our results implicate RhoB as a novel intermediate in critical signaling pathways and as an additional target for therapeutic intervention in ATC.
AuthorsLaura A Marlow, Lisa A Reynolds, Alan S Cleland, Simon J Cooper, Michelle L Gumz, Shinichi Kurakata, Kosaku Fujiwara, Ying Zhang, Thomas Sebo, Clive Grant, Bryan McIver, J Trad Wadsworth, Derek C Radisky, Robert C Smallridge, John A Copland
JournalCancer research (Cancer Res) Vol. 69 Issue 4 Pg. 1536-44 (Feb 15 2009) ISSN: 1538-7445 [Electronic] United States
PMID19208833 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • PPAR gamma
  • Thiazolidinediones
  • rhoB GTP-Binding Protein
  • efatutazone
Topics
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Carcinoma (drug therapy, genetics, pathology)
  • Cell Division
  • Cell Line, Tumor
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Lentivirus (genetics)
  • Mice
  • PPAR gamma (agonists, genetics)
  • Reverse Transcriptase Polymerase Chain Reaction
  • Suppression, Genetic
  • Thiazolidinediones (pharmacology)
  • Thyroid Neoplasms (drug therapy, genetics, pathology)
  • Transplantation, Heterologous
  • rhoB GTP-Binding Protein (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: